Table 3.

Associations between clinicopathological factors and overall survival among docetaxel-treated gastric cancer patients

Clinicopathological factors	Short time survival, hazard ratio	95 % confidence interval	p value
CHFR
CHFR unmethylation	1.000
CHFR methylation	0.243	0.069–0.859	0.028*
Gender
Male	1.000
Female	2.115	0.555–8.062	0.272
Age (years)
n < 60	1.000
n ≥ 60	1.215	0.289–5.113	0.790
Tumor histology
Intestinal type	1.000
Diffused and mixed type	0.815	0.391–1.701	0.586
Differentiation
Well and moderately differentiated	1.000
Poorly differentiated	1.997	0.440–9.061	0.370
Tumor size
d < 5	1.000
d ≥ 5	0.351	0.107–1.149	0.084
Tumor invasion
T1–T2	1.000
T3–T4	2.729	0.527–14.121	0.231
Lymph node metastasis
N0–N1	1.000
N2–N3	1.550	0.785–3.060	0.206
Peritoneal or distant metastasis
M0	1.000
M1	4.048	0.256–64.064	0.321
Tumor stage
I–II	1.000
II–IV	0.300	0.038–2.353	0.252
Vessel invasion
Negative	1.000
Positive	0.837	0.200–3.508	0.808

The multivariate Cox regression model showed that CHFR methylation was associated with a decreased (75.7 %) risk of shorter overall survival compared to CHFR unmethylation (HR 0.243, 95 % CI, 0.069–0.859, p = 0.028; Table 3) in docetaxel-treated gastric cancer patients. No significant association between the other clinicopathological factors and overall survival was observed